{
    "2018-10-24": [
        [
            {
                "time": "2018-10-24",
                "original_text": "Incyte (INCY) to Report Q3 Earnings: What's in the Cards?",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Q3 Earnings",
                        "Report"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-24",
                "original_text": "A Performance Overview of Johnson & Johnson",
                "features": {
                    "keywords": [
                        "Performance",
                        "Overview",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-25",
                "original_text": "Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG",
                "features": {
                    "keywords": [
                        "Drug Stocks",
                        "Earnings",
                        "MRK",
                        "BMY",
                        "GILD",
                        "CELG"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-24",
                "original_text": "What Analysts Recommend for Novartis after Q3 Earnings",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommend",
                        "Novartis",
                        "Q3 Earnings"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}